Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG579

—

21c35a88-f8a7-5353-b867-d869e3cdcdbb

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • OXIDATIVE_PHOSPHORYLATION+0.515
  • PROTEIN_SECRETION+0.492
  • TGF_BETA_SIGNALING+0.371
  • ADIPOGENESIS+0.370
  • UNFOLDED_PROTEIN_RESPONSE+0.315
  • HEME_METABOLISM+0.285
  • MYC_TARGETS_V1+0.250
  • UV_RESPONSE_DN+0.245
  • NOTCH_SIGNALING+0.242
  • P53_PATHWAY+0.213

Top 10 suppressed

  • APICAL_SURFACE-0.330
  • E2F_TARGETS-0.306
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.282
  • ALLOGRAFT_REJECTION-0.281
  • IL6_JAK_STAT3_SIGNALING-0.266
  • MYC_TARGETS_V2-0.259
  • PANCREAS_BETA_CELLS-0.255
  • G2M_CHECKPOINT-0.254
  • INTERFERON_GAMMA_RESPONSE-0.241
  • KRAS_SIGNALING_DN-0.231

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG1034
mng-umap@100
——0.809
2R319
bladder-landscape@3
——0.790
3MNG1007
mng-umap@100
——0.777
4MNG1214
mng-umap@100
——0.769
5SJEPD030908_D1.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.737
6TCGA-BH-A0BS-01A-11R-A12P-07
breast-umap@18
—B0.737
7MNG1024
mng-umap@100
——0.724
8DRR168548
bladder-landscape@3
——0.723
9s_150324_7c
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.715
10MDT-AP-1189
medullo-epn-umap@date-based
MedMedulloblastoma0.714

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 29 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
OXIDATIVE_PHOSPHORYLATION0.515Remibrutinib— uncovered
PROTEIN_SECRETION0.492Remibrutinib— uncovered
TGF_BETA_SIGNALING0.371Inavolisib— uncovered
ADIPOGENESIS0.370Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.315Idelalisib— uncovered
HEME_METABOLISM0.285Temsirolimus— uncovered
MYC_TARGETS_V10.250Inavolisib— uncovered
UV_RESPONSE_DN0.245Inavolisib— uncovered
NOTCH_SIGNALING0.242Inavolisib— uncovered
P53_PATHWAY0.213Idelalisib— uncovered
FATTY_ACID_METABOLISM0.199Inavolisib— uncovered
APOPTOSIS0.178Idelalisib— uncovered
BILE_ACID_METABOLISM0.161Inavolisib— uncovered
MTORC1_SIGNALING0.159Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.158Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.157Inavolisib— uncovered
ANGIOGENESIS0.145Remibrutinib— uncovered
DNA_REPAIR0.144Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.136Inavolisib— uncovered
UV_RESPONSE_UP0.106Idelalisib— uncovered